Abstract
India has the highest burden of both tuberculosis (TB) and Multidrug Resistant tuberculosis (MDR-TB), based on estimates reported in Global TB Report 2016. Conventional diagnostic techniques are less sensitive & time consuming. The Xpert MTB/RIF Assay has the capacity to revolutionize the diagnosis of TB because of its speed, sensitivity and specificity. The objectives of our study are to determine the rate of positivity of Mycobacterial tuberculosis complex among the different clinical specimen and to know the rate of Rifampicin resistance among these specimens by using Xpert MTB/RIF Assay. The study was conducted in Department of Microbiology, Rural Medical College, (PIMS), Loni. Clinical Samples from suspected TB cases were treated according to Manufacturer’s Instructions & Standard operating procedure. A total of 1528 Samples received during the study period out of which 267 (17.47%) were positive for complex (MTBC) and 15 (0.98%) were rifampicin resistant. Maximum positivity was noted in age group 21-30 years. Out of total 126 extrapulmonary specimens, 10 were positive for MTBC. Also out of 273 HIV infected cases 16 samples were positive for MTBC while 1 was Rifampicin resistant.Accurate early diagnosis and treatment of TB has the potential to reduce morbidity and mortality associated with MDR TB. Xpert MTB /RIF assay has brought revolution in the earliest diagnosis (Turn around time-2.5hrs) compared to culture (which takes weeks) with simultaneous drug susceptibility testing.
Highlights
India has the highest burden of both tuberculosis (TB) and Multidrug Resistant tuberculosis (MDR-TB), based on estimates reported in Global TB Report 2016
India has the highest burden of both TB and Multidrug Resistant tuberculosis (MDR-TB), based on estimates reported in Global TB Report 2016 (0.13 million of 0.48 million of cases of MDRTB). 3 Multi-drug resistant (MDR) tuberculosis is defined as TB disease caused by a strain of Mycobacterium tuberculosis that is resistant to at least isoniazid and rifampicin (RIF)
A total of 1528 Samples received during this period out of which 267 (17.47%) were positive for Mycobacterium tuberculosis complex on GeneXpert
Summary
India has the highest burden of both tuberculosis (TB) and Multidrug Resistant tuberculosis (MDR-TB), based on estimates reported in Global TB Report 2016. The objectives of our study are to determine the rate of positivity of Mycobacterial tuberculosis complex among the different clinical specimen and to know the rate of Rifampicin resistance among these specimens by using Xpert MTB/RIF Assay. Result: A total of 1528 Samples received during the study period out of which 267 (17.47%) were positive for Mycobacterium tuberculosis complex (MTBC) and 15 (0.98%) were rifampicin resistant. Out of 273 HIV infected cases 16 samples were positive for MTBC while 1 was Rifampicin resistant. India has the highest burden of both TB and Multidrug Resistant tuberculosis (MDR-TB), based on estimates reported in Global TB Report 2016 (0.13 million of 0.48 million of cases of MDRTB). Most deaths due to TB can be prevented if patient receives timely management
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: IP International Journal of Medical Microbiology and Tropical Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
